Table 1:

Clinical and demographic data

Patient No.SexAge (yr)Clinical PhenotypeEDSSDisease Duration (yr)Disease-Modifying Treatment
1Female60RR1.511Dimethyl fumarate
2Female66Progressive728None
3Male56Progressive624None
4Male47RR1.516Daclizumab
5Female43RR243None
6Female64RR1.59None
7Female55RR1.52Interferon β-1a
8Male36RR17Glatiramer acetate
9Male61Progressive6.540None
10Female51Progressive6.524None
11Female35RR14Dimethyl fumarate
12Female36RR2.518Glatiramer acetate
13Male38RR01None
14Female28RR1.51None
15Female33RR21None
16Female42RR2.510Mycophenolate mofetil
17Female25RR21Glatiramer acetate
18Female30RR1.58None
19Female36RR1.59Dimethyl fumarate
20Female71RR115None
  • Note:—RR indicates relapsing-remitting.